A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL).
John Leonard
Consultant or Advisory Role - Gilead Sciences
Research Funding - Gilead Sciences
Pier Luigi Zinzani
Research Funding - Gilead Sciences
Wojciech Jurczak
Research Funding - Gilead Sciences
Mathias J. Rummel
Research Funding - Gilead Sciences
Gilles A. Salles
Consultant or Advisory Role - Gilead Sciences
Research Funding - Gilead Sciences
Eva Kimby
Research Funding - Gilead Sciences
Hendrik-Tobias Arkenau
Research Funding - Gilead Sciences
Andrew John Davies
Research Funding - Gilead Sciences
David Michael Johnson
Employment or Leadership Position - Gilead Sciences
Shelley Evans
Employment or Leadership Position - Gilead Sciences
Roger D. Dansey
Employment or Leadership Position - Gilead Sciences
Wayne R. Godfrey
Employment or Leadership Position - Gilead Sciences
Brad S. Kahl
Consultant or Advisory Role - Gilead Sciences
Research Funding - Gilead Sciences